

BOND-003 | Cohort P | A Phase 3, Single-Arm Study of Cretostimogene Grenadenorepvec for the Treatment of Papillary NMIBC without Carcinoma in Situ, Unresponsive to BCG

Mark D. Tyson, MD, MPH,¹ Woodson W. Smelser, MD,² Rian J. Dickstein, MD,³ Daniel E. Zainfeld, MD,⁴

Jee-Hyun Kim, PhD,⁵ Kirk A. Keegan, MD, MPH,⁵ and Roger Li, MD⁶


¹Mayo Clinic, Scottsdale, Arizona, ²Washington University, St. Louis, Missouri, ³Chesapeake Urology, Hanover, Maryland,

⁴Urology San Antonio,

⁶Center, Tampa Florida

BACKGROUND

- Cretostimogene is a conditionally replicating, intravesically delivered adenovirus
- Oncolytic immunotherapy: Cretostimogene is engineered to selectively replicate and lyse Rb-altered bladder cancer cells and produce GM-CSF, stimulating the immune system via a dual mode of action
- In High Risk NMIBC, including CIS +/- HG Ta/T1 tumors, cretostimogene shows Complete Response rates between 46-85%¹⁻⁴



References: ¹ Burke, *J Uro*; 2012, ² Packiam, *Uro Onc*; 2018, ³ Li, *AUA Meeting*; 2022,

⁴ Tyson, *SUO Meeting*; 2023

BOND-003

Trial in Progress


Significant Unmet Need In BCG-UR Papillary NMIBC

35+ sites Globally



Oncolytic Immunotherapy: Selective Oncolysis and Potent Anti-Tumor Immune Response


1 Targets and Destroys Cancer Cells



Spreads to additional tumor cells inducing a chain reaction of killing cancer cells

Virus stimulates cytokines and antigens from dying cancer cells which activates T-cells inducing tumor cell death and destruction

STUDY DESIGN



- Enrolling up to 70 patients with HG Ta/T1 papillary disease without CIS
- BCG unresponsive defined as recurrent HG Ta/T1 within 6 month of last adequate BCG dose
- Primary endpoint Event Free Survival
- Robust patient reported outcomes and biomarkers

Study Administration

	Induction 1		Induction 2		Maintenance / Follow-Up				
Month	0	3	6	9	12	15	18	21	24/30/36
Instillation	1 2 3 4 5 6	1 2 3 (4 5 6)	1 2 3	1 2 3	1 2 3	1 2 3	1 2 3	1 2 3	1 2 3

Acknowledgements: Shelly Basye, MD, Andy Darilek, MD, Jee-Hyun Kim, PhD, Nataliya Hnat, MD, Maira Ansari, John McAdory, Gigi Palomera, DNP, JoAnn Horn, Kyle Rice, Michael Lambert, Kara Sabourin, and Vijay Kasturi, MD

Contact Information: Mark Tyson, MD, MPH, BOND 003 Global PI, Tyson.Mark@mayo.edu

